EPISODE · Jun 24, 2026 · 31 MIN
#535 - Why is chronic disease still winning? | Mark Clermont (CEO, Cecelia Health) & Wendi Mader (CCO)
from Slice of Healthcare · host Slice of Media, Inc.
Mark Clermont is the CEO of Cecelia Health, and Wendi Mader is the company's Chief Commercial Officer. Cecelia is a virtual multi-specialty medical practice, licensed in all 50 states, that helps employers, payers, health systems, and life sciences companies manage chronic and cardiometabolic disease and bring down the cost of care. It's not a point solution. It's a medical practice that prescribes and manages medication (including GLP-1s, from prescribing through titration and side-effect management), runs intensive nutrition therapy, and handles behavior and lifestyle care, all through a team of RNs, RDs, certified diabetes educators, and physicians. The model is built to extend primary care, not replace it, and to coordinate across specialists instead of adding one more disconnected program.Mark and Wendi's argument is simple: chronic disease isn't winning because we lack apps or tools. It's winning because care is fragmented and nobody's tying it together. GLP-1s are making that worse before they make it better. They're the first drug class with indications spanning diabetes, obesity, sleep apnea, fatty liver, and soon addiction, which means a single patient can suddenly need four specialists who don't talk to each other. Cecelia's bet is that a multi-specialty practice can be the layer that connects all of it.We get into:Why chronic disease keeps winning even though there are more apps, tools, and wellness programs than ever, and what point solutions got wrongWhat actually happens to a patient with diabetes and high blood pressure inside Cecelia's model versus the system todayWhy GLP-1s are the first drug class to cross medical specialties, and why that's making fragmentation worse right nowThe patient on a high-dose GLP-1 and an SSRI who almost ended up in the ER, and what the direct-to-consumer prescriber missedHow the US can rank dead last among developed nations and still be the system Mark wouldn't trade for anywhere elseWhere the industry is over-indexing on AI in chronic care, and where Wendi thinks tech actually belongsThe specialty shortage, healthcare deserts, and rural-health funding, and how virtual coordinated care reaches patients brick-and-mortar can'tWhat's different for patients five years from now if Cecelia gets this right—Brought to you by: Sage Growth Partners — Value-focused strategy and marketing for growth-driven healthcare organizations. — Where to find Jared: • X: https://x.com/jaredstaylor • LinkedIn: https://www.linkedin.com/in/jaredstaylor/
What this episode covers
Mark Clermont is the CEO of Cecelia Health, and Wendi Mader is the company's Chief Commercial Officer. Cecelia is a virtual multi-specialty medical practice, licensed in all 50 states, that helps employers, payers, health systems, and life sciences companies manage chronic and cardiometabolic disease and bring down the cost of care. It's not a point solution. It's a medical practice that prescribes and manages medication (including GLP-1s, from prescribing through titration and side-effect management), runs intensive nutrition therapy, and handles behavior and lifestyle care, all through a team of RNs, RDs, certified diabetes educators, and physicians. The model is built to extend primary care, not replace it, and to coordinate across specialists instead of adding one more disconnected program.Mark and Wendi's argument is simple: chronic disease isn't winning because we lack apps or tools. It's winning because care is fragmented and nobody's tying it together. GLP-1s are making that worse before they make it better. They're the first drug class with indications spanning diabetes, obesity, sleep apnea, fatty liver, and soon addiction, which means a single patient can suddenly need four specialists who don't talk to each other. Cecelia's bet is that a multi-specialty practice can be the layer that connects all of it.We get into:Why chronic disease keeps winning even though there are more apps, tools, and wellness programs than ever, and what point solutions got wrongWhat actually happens to a patient with diabetes and high blood pressure inside Cecelia's model versus the system todayWhy GLP-1s are the first drug class to cross medical specialties, and why that's making fragmentation worse right nowThe patient on a high-dose GLP-1 and an SSRI who almost ended up in the ER, and what the direct-to-consumer prescriber missedHow the US can rank dead last among developed nations and still be the system Mark wouldn't trade for anywhere elseWhere the industry is over-indexing on AI in chronic care, and where Wendi thinks tech actually belongsThe specialty shortage, healthcare deserts, and rural-health funding, and how virtual coordinated care reaches patients brick-and-mortar can'tWhat's different for patients five years from now if Cecelia gets this right—Brought to you by: Sage Growth Partners — Value-focused strategy and marketing for growth-driven healthcare organizations. — Where to find Jared: • X: https://x.com/jaredstaylor • LinkedIn: https://www.linkedin.com/in/jaredstaylor/
NOW PLAYING
#535 - Why is chronic disease still winning? | Mark Clermont (CEO, Cecelia Health) & Wendi Mader (CCO)
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.